Senl 1904B
Alternative Names: 1904B CAR-T; Anti CD19 chimeric antigen receptor T-cell therapy Senl_1904B - Hebei Senlang Biotechnology; Autologous CD19-targeting CAR T cell therapy - Hebei Senlang Biotechnology; CAR-γδT cell injection - Hebei Senlang Biotechnology; CD19 CAR-T - Hebei Senlang Biotechnology; Senl-1904B; Senl_1904B; Senl_1904B CD19 CAR-T cell therapy - Hebei Senlang Biotechnology; SL1904BLatest Information Update: 28 Jan 2024
Price :
$50 *
At a glance
- Originator Hebei Senlang Biotechnology
- Developer Hebei Senlang Biotechnology; Hebei Yanda Lu Daopei Hospital
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I/II Precursor cell lymphoblastic leukaemia-lymphoma
- No development reported Acute myeloid leukaemia; Non-Hodgkin's lymphoma
Most Recent Events
- 28 Jan 2024 No recent reports of development identified for clinical-Phase-Unknown development in Acute-myeloid-leukaemia(In adolescents, In children, Second-line therapy or greater, In adults) in China (IV, Infusion)
- 28 Oct 2023 No recent reports of development identified for clinical-Phase-Unknown development in Precursor-cell-lymphoblastic-leukaemia-lymphoma(Second-line therapy or greater) in China (IV, Infusion)
- 28 Jul 2023 No recent reports of development identified for clinical-Phase-Unknown development in Non-Hodgkin's-lymphoma(Second-line therapy or greater) in China (IV, Infusion)